Topical use of pimecrolimus in atopic dermatitis;Topische Anwendung von Pimecrolimus bei atopischer Dermatitis: Ein Update zur Sicherheit und Wirksamkeit

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 9, 2009, Pages 739-742

  Werfel, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Atopic dermatitis; Guidelines; Pimecrolimus; Safety; Sensitive skin area

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE; PIMECROLIMUS; PLACEBO; PREDNICARBATE; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ATOPIC DERMATITIS; BURNING SENSATION; CANCER RISK; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERANCE; FACE; FOOD AND DRUG ADMINISTRATION; HERPES SIMPLEX; HUMAN; INCIDENCE; LYMPHOMA; PERIORAL DERMATITIS; RECURRENT INFECTION; REVIEW; ROSACEA; SCALP; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SKINFOLD THICKNESS; STRIAE DISTENSAE; TREATMENT DURATION; VIRUS INFECTION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; DRUG ERUPTIONS; HUMANS; RISK ASSESSMENT; TACROLIMUS;

EID: 69549138253     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07141.x     Document Type: Review

References (22)

1. Werfel T, Aberer W, Augustin M, Bidermann T, Fölster-Holst R, Friedrichs F, Gieler U, Heratizadeh A, Kapp A, Przybilla B, Rietschel E, Schlaeger M, Schmid-Grendelmeier P, Sitters H, Staab D, Szczepanski R, Vieluf D, Voigtmann I, Worm M. S2-Leitlinie Neurodermitis (2008) http://www.leitlinien. net und J Dt Dermatol Ges, Suppl 1 2009-04-08.
2. Murrell DF, Calvieri S, Ortonne JP, HO VC, Weise-Riccardi S, Barbier N, Paul C. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007 157 : 954 959.
3. Zuberbier T, Braeutigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008 22 : 718 721.
4. Ring J, Abraham A, de Cuyper C, Kim K, Langeland T, Parra V, Pigatto P, Reunala T, Szczepanski R, Möhrenschlager M, Bräutigam M, Rossi AB, Meents-Kopecky E, Schneider D. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. J Eur Acad Dermatol Venereol 2008 22 : 195 203.
5. Gollnick H, Kaufmann R, Stough D, Heikkila H, Andriano K, Grinienko A, Jimenez P. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008 158 : 1083 1093.
6. Doelker L, Tran C, Gkomouzas A, Grand D, Sorg O, Saurat JH, Lübbe J al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006 15 : 342 346.
7. Langley RG, Luger TA, Cork MJ, Schneider D, Paul C. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007 215, Suppl 1 : 27 44.
8. Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr Drugs 2007 9 : 289 299.
9. Ring J, Mohrenschlager M and Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008 31 : 185 198.
10. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 127 : 808 816.
11. Margolis DJ, Hoffstad O and Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007 214 : 289 295.
12. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002 204 : 63 68.
13. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 144 : 781 787.
14. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin M-E, Burtin P, Stephenson TJ. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 88 : 969 973.
15. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch Th, Graeber M, Cherill R, de Prost Y. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
16. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 144 : 788 794.
17. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 144 : 507 513.
18. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004 15 : 169 178.
19. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S, Abrams B. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 : 51 : 515 525.
20. Garside R, Stein K, Castelnuovo E, Pitt M, Ashcroft D, Dimmock P, Payne L. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 9 : iii, xi xiii, 1 230.
21. Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, Murrell, DF, Gebauer K, Behre U, Machura, E, Olafsson J, Szalai Z. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006 91 : 905 910.
22. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, Miles F, Davidson J, Barbier N, Goertz HP, Paul C. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005 52 : 247 253.